Current Urology Reports

, 19:67 | Cite as

The Role of Testosterone Therapy in the Setting of Prostate Cancer

  • Katherine M. Rodriguez
  • Alexander W. Pastuszak
  • Mohit KheraEmail author
Andrology and Infertility (L Lipshultz, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Andrology and Infertility


Purpose of Review

The role of testosterone in the development of prostate cancer and the safety of testosterone therapy (TTh) after prostate cancer treatment, or in the setting of active surveillance, remains controversial. There are many concerns about using TTh in men, particularly those with a history of prostate cancer, ranging from a possible increased risk of cardiovascular disease to cancer progression or recurrence. With many prostate cancer patients living longer, and hypogonadism having significant morbidity, much care must go into the decision to treat. Here, we review the literature investigating the effects of testosterone on the prostate as well as the efficacy and safety of exogenous testosterone in men with a history of prostate cancer.

Recent Findings

The improvement in quality of life with TTh is well studied and understood, while the argument for significantly increased risk of cancer or other adverse effects is much less robust. Neither increased rates of prostate cancer, cancer recurrence, or cardiovascular risk have been well established. In men with high-risk prostate cancer, evidence in the setting of TTh is very limited, and TTh should be used with caution.


The fears of TTh causing or worsening prostate cancer do not appear to be well supported by available data. Though more studies are needed to definitively determine the safety of TTh in men with prostate cancer, consideration should be given to treatment of hypogonadal men with a history of CaP.


Hypogonadism Testosterone Hormone replacement Prostate cancer Prostatectomy Radiation therapy 



Androgen receptor


Digital rectal examination


Prostate cancer


Prostate-specific antigen


Testosterone therapy


Active surveillance


Compliance with Ethical Standards

Conflict of Interest

Katherine Rodriguez, Alexander W. Pastuszak, and Mohit Khera each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the effects of testosterone gels, injections, and pellets on serum hormones, erythrocytosis, lipids, and prostate-specific antigen. Sex Med. 2015;3(3):165–73.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195–200.CrossRefPubMedGoogle Scholar
  7. 7.
    Cunningham GR, et al. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990;70(3):792–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639–44.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Storer TW, Woodhouse L, Magliano L, Singh AB, Dzekov C, Dzekov J, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc. 2008;56(11):1991–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11(6):1577–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Investig. 2015;38(1):103–12.CrossRefGoogle Scholar
  12. 12.
    Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465–6.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    •• Boyle P, et al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int. 2016 A well-done meta-analysis including available literature to 2016. Includes both increase in occult CaP and PSA increase. Google Scholar
  14. 14.
    Huggins C, Hodges CV. Studies on prostatic cancer. J Urol. 2002;167(2):948–51.CrossRefPubMedGoogle Scholar
  15. 15.
    Prout GR, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer. 1967;20(11):1871–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Fowler Jr J, Whitmore Jr W. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126(3):372–5.CrossRefGoogle Scholar
  17. 17.
    Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(6):1995–2010.CrossRefPubMedGoogle Scholar
  18. 18.
    Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. Jama. 1996;276(23):1904–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol. 2015;193(2):403–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006;68(6):1263–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Shin BS, Hwang EC, Im CM, Kim SO, Jung SI, Kang TW, et al. Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of Korean men. Korean J Urol. 2010;51(12):819–23.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mearini L, Zucchi A, Nunzi E, Villirillo T, Bini V, Porena M. Low serum testosterone levels are predictive of prostate cancer. World J Urol. 2013;31(2):247–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Bayar G, Sirin H, Aydin M, Ozagari A, Tanriverdi O, Kadihasanoglu M, et al. Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial. Turk J Urol. 2017;43(3):289–96.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Garcia-Cruz E, et al. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int. 2012;110(11 Pt B):E541–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Albuquerque G, et al. Low serum testosterone is a predictor of high-grade disease in patients with prostate cancer. Rev Assoc Med Bras (1992). 2017;63(8):704–10.CrossRefGoogle Scholar
  26. 26.
    Izumi K, Shigehara K, Nohara T, Narimoto K, Kadono Y, Mizokami A. Both high and low serum total testosterone levels indicate poor prognosis in patients with prostate cancer. Anticancer Res. 2017;37(10):5559–64.PubMedGoogle Scholar
  27. 27.
    Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, et al. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. Clin Cancer Res. 2012;18(13):3648–57.CrossRefPubMedGoogle Scholar
  28. 28.
    Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88(16):1118–26.CrossRefPubMedGoogle Scholar
  29. 29.
    Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol. 2000;18(4):847–53.CrossRefPubMedGoogle Scholar
  30. 30.
    Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol. 2007;51(2):375–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol. 2012;62(5):757–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Platz EA, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomark Prev. 2005;14(5):1262–9.CrossRefGoogle Scholar
  33. 33.
    Roddam AW, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3):170–83.CrossRefPubMedGoogle Scholar
  34. 34.
    Stattin P, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004;108(3):418–24.CrossRefPubMedGoogle Scholar
  35. 35.
    Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, et al. Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int. 2008;80(2):134–40.CrossRefPubMedGoogle Scholar
  36. 36.
    Ahmadi H, Allameh F, Baradaran N, Montaser-Kouhsari L, Bazargan-Hejazi S, Salem S, et al. Circulating sex hormones play no role in the association between sexual activity and the risk of prostate cancer. J Sex Med. 2011;8(3):905–13.CrossRefPubMedGoogle Scholar
  37. 37.
    Porcaro AB, Petrozziello A, Ghimenton C, Migliorini F, Sava T, Caruso B, et al. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer. Urol Int. 2014;93(3):269–78.CrossRefPubMedGoogle Scholar
  38. 38.
    Porcaro AB, Petroziello A, Brunelli M, de Luyk N, Cacciamani G, Corsi P, et al. High testosterone preoperative plasma levels independently predict biopsy Gleason score upgrading in men with prostate cancer undergoing radical prostatectomy. Urol Int. 2016;96(4):470–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Salonia A, Abdollah F, Capitanio U, Gallina A, Suardi N, Briganti A, et al. Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World J Urol. 2013;31(2):275–80.CrossRefPubMedGoogle Scholar
  40. 40.
    Roder MA, et al. Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. BJU Int. 2012;109(4):520–4.CrossRefPubMedGoogle Scholar
  41. 41.
    Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52(3):696–701.CrossRefPubMedGoogle Scholar
  42. 42.
    Imamoto T, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J. 2001;48(5):573–8.CrossRefPubMedGoogle Scholar
  43. 43.
    • Cooper CS, Perry PJ, Sparks AET, MacIndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998;159(2):441–3. One of the early studies that set the stage for the set point theory.–3.Google Scholar
  44. 44.
    •• Dupree, J.M., et al., The safety of testosterone supplementation therapy in prostate cancer. Nat Rev Urol, 2014. 11(9): p. 526–30. A comprehensive and well-written review from 2014. Google Scholar
  45. 45.
    • Song W, Khera M. Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl. 2014;16(6):864–8. In vitro data that adds to the understanding of the relationship between CaP and testosterone. CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    •• Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50(5):935–9. An interesting review put into the context of historial concerns and modern literature. CrossRefPubMedGoogle Scholar
  47. 47.
    Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med. 2014;11(11):2818–25.CrossRefPubMedGoogle Scholar
  48. 48.
    Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186(3):1005–11.CrossRefPubMedGoogle Scholar
  49. 49.
    Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Yassin A, Salman M, Talib RA, Yassin DJ. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. Aging Male. 2017;20(2):125–33.CrossRefPubMedGoogle Scholar
  51. 51.
    Wallis CJ, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4(6):498–506.CrossRefPubMedGoogle Scholar
  52. 52.
    Debruyne FM, et al. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int. 2017;119(2):216–24.CrossRefPubMedGoogle Scholar
  53. 53.
    Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol. 2017;35(13):1430–6.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920–2.CrossRefPubMedGoogle Scholar
  55. 55.
    Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6(4):1165–70.CrossRefPubMedGoogle Scholar
  56. 56.
    Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536–41.CrossRefPubMedGoogle Scholar
  57. 57.
    Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 2009;103(1):62–4.CrossRefPubMedGoogle Scholar
  58. 58.
    Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25(1):24–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int. 2014;114(1):125–30.CrossRefPubMedGoogle Scholar
  60. 60.
    Ory J, Flannigan R, Lundeen C, Huang JG, Pommerville P, Goldenberg SL. Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes. J Urol. 2016;196:1082–9.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185(4):1256–60.CrossRefPubMedGoogle Scholar
  62. 62.
    Kacker R, Hult M, San Francisco IF, Conners WP, Rojas PA, Dewolf WC, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016;18(1):16–20.CrossRefPubMedGoogle Scholar
  63. 63.
    Pastuszak AW, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners WP, et al. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol. 2015;194(5):1271–6.CrossRefPubMedGoogle Scholar
  64. 64.
    Golla V, Kaplan AL. Testosterone therapy on active surveillance and following definitive treatment for prostate cancer. Curr Urol Rep. 2017;18(7):49.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990–2013. Jama. 2015;314(1):80–2.CrossRefPubMedGoogle Scholar
  66. 66.
    Fowler, J.E., Jr. and W.F. Whitmore, Jr., Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer, 1982. 49(7): p. 1373–7.Google Scholar
  67. 67.
    • Mohammad OS, et al. Supraphysiologic testosterone therapy in the treatment of prostate cancer: models mechanisms, and questions. Cancers (Basel). 2017;9(12). Interesting paper supporting the emerging bipolar androgen therapy hypothesis. Google Scholar
  68. 68.
    Geck P, Maffini MV, Szelei J, Sonnenschein C, Soto AM. Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. Proc Natl Acad Sci U S A. 2000;97(18):10185–90.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Soto AM, Sonnenschein C. The two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst. 2001;93(22):1673–5.CrossRefPubMedGoogle Scholar
  70. 70.
    Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci. 1996;93(21):11802–7.CrossRefPubMedGoogle Scholar
  71. 71.
    Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett. 1995;96(2):239–43.CrossRefPubMedGoogle Scholar
  72. 72.
    Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol. 2009;56(2):237–44.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009;56(1):97–103.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate. 2010;70(14):1600–7.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Mohammad OS, et al. Supraphysiologic testosterone therapy in the treatment of prostate cancer: models, mechanisms and questions. Cancers. 2017;9(12):166.CrossRefPubMedCentralGoogle Scholar
  76. 76.
    Schweizer, M.T., et al., Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med, 2015. 7(269): p. 269ra2.Google Scholar
  77. 77.
    Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, et al. Bipolar androgen therapy for men with androgen ablation naive prostate cancer: results from the phase II BATMAN study. Prostate. 2016;76(13):1218–26.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Katherine M. Rodriguez
    • 1
  • Alexander W. Pastuszak
    • 2
    • 3
  • Mohit Khera
    • 3
    Email author
  1. 1.Baylor College of MedicineHoustonUSA
  2. 2.Center for Reproductive MedicineBaylor College of MedicineHoustonUSA
  3. 3.Scott Department of UrologyBaylor College of MedicineHoustonUSA

Personalised recommendations